Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant

J Invest Dermatol. 1997 Jun;108(6):933-7. doi: 10.1111/1523-1747.ep12295238.


Modified, non-neurovirulent herpes simplex viruses (HSV) have shown promise for the treatment of brain tumors, including intracranial melanoma. In this report, we show that HSV-1716, an HSV-1 mutant lacking both copies of the gene coding-infected cell protein 34.5 (ICP 34.5), can effectively treat experimental subcutaneous human melanoma in mice. In vitro, HSV-1716 replicated in all 26 human melanoma cell lines tested, efficiently lysing the cells. Therapeutic infection of subcutaneous human melanoma nodules with HSV-1716 led to viral replication that was restricted to tumor cells by immunohistochemistry. Moreover, HSV-1716 treatment significantly inhibited progression of preformed subcutaneous human melanoma nodules in SCID mice and caused complete regression of some tumors. This work expands the potential scope of HSV-1-based cancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Analysis of Variance
  • Animals
  • Antigens, Viral / analysis
  • Cell Death / physiology
  • DNA, Viral / analysis
  • DNA, Viral / chemistry
  • DNA, Viral / genetics
  • Herpesvirus 1, Human / genetics*
  • Herpesvirus 1, Human / isolation & purification
  • Herpesvirus 1, Human / physiology*
  • Humans
  • Immunohistochemistry
  • Melanoma / pathology
  • Melanoma / therapy*
  • Melanoma / virology
  • Mice
  • Mice, SCID
  • Mutation*
  • Neoplasm Regression, Spontaneous / pathology
  • Neoplasm Transplantation
  • Skin Neoplasms / pathology
  • Skin Neoplasms / therapy*
  • Skin Neoplasms / virology
  • Tumor Cells, Cultured
  • Virus Replication


  • Antigens, Viral
  • DNA, Viral